Noramco, a major producer of specialty active pharmaceutical ingredients (APIs), has announced it plans to drive three strategic growth vectors. Noramco will focus efforts in geographic expansion, solutions capabilities and will establish new development and manufacturing platforms for generic and branded customers. At the DCAT Association meeting in New York, the company will also highlight novel technology for efficient synthesis of cannabinoid-based APIs - the molecules pharmaceutical companies are investigating in clinical trials, including those involving neurological disorders.

Following its establishment as an independent business, Noramco has moved at an accelerated pace to develop new routes to high-purity API manufacture. The company has begun to leverage its decades of expertise in natural-to-synthetic conversion technology to include other high-purity API production processes capable of unlocking extra value for pharmaceutical companies.

Noramco will also announce its plan to serve as a provider of technology solutions. The company’s new management is transitioning the company from a pure-play producer of controlled substances to a business that delivers "enabling science" to pharmaceutical companies through an integrated API development, manufacture, and regulatory service offering.

“Noramco is repositioning the company to serve as an innovation partner to the pharmaceutical industry, while still focusing 100 per cent on the API market,” said Bill Grubb, vice president, global business development. “Leveraging our API knowledge to provide solutions to stability, bioavailability, and purity challenges will benefit our customers. Every material we make and every technology solution we provide will be designed to solve problems and accelerate customers’ commercial projects. This will happen at an accelerated pace with additional focus on geographic expansion into emerging markets.”

James Mish, president and chief executive officer of Noramco, will present the company’s new mission, strategy, and technology offering during the DCAT Member Company Announcement Forum, Monday, March 20, Omni Berkshire Hotel, New York.